Kintor Pharmaceutical Limited a yau ta sanar da cewa kamfanin ya kammala rajistar majinyata 160 don gwajin gwajin gwaji na kashi na II na KX-826 (“pyrilutamide”) a kasar Sin don kula da alopecia na mace (AGA) a ranar 4 ga Maris 2022, wanda ya samu kawai. ya dauki kusan watanni hudu da kaddamar da shi.
Yawan mutanen da ke fama da asarar gashi suna da adadi mai yawa kuma suna da yawa, kuma raguwar gashi a hankali ya zama abin mayar da hankali ga al'umma gaba daya. Ya zuwa karshen shekarar 2020, yawan asarar gashi a kasar Sin ya zarce miliyan 252. AGA, wanda aka fi sani da nau'in asarar gashi, yanayi ne da zai iya shafar maza da mata. A China, yawan AGA ya kai kusan 21.3% a cikin maza da 6.0% a cikin mata*.
Dr. Youzhi Tong, wanda ya kafa, Shugaba, kuma Shugaba na Kintor Pharma yayi sharhi, "Mun yi farin cikin ganin kammala rajista na dukkan batutuwa a cikin gwaji na asibiti na kashi II na KX-826, kuma ina so in yi godiya ta musamman. duk masu bincike, batutuwa da ƙungiyara waɗanda suka shiga cikin wannan gwaji na asibiti. A kasar Sin, daya daga cikin manyan mata 20 na fama da asarar gashi, kuma adadin da ake samu a cikin manya ya kai 5:1. Rashin gashi yana da tasiri mai mahimmanci akan lafiyar kwakwalwar marasa lafiya da ingancin rayuwa. Muna sa ran samun bayanan farko daga wannan binciken a cikin Q4 a wannan shekara, tare da kara fadada yiwuwar asibiti na KX-826 a cikin mata masu fama da AGA, da kuma hanzarta gwajin gwaji na KX-826 na III na asibiti ga majin AGA na maza a kasar Sin, don saduwa da magance bukatun mutanen da ke fama da asarar gashi da wuri-wuri."
Gwajin gwaji na II shine bazuwar, makafi biyu, mai sarrafa wuribo, nazarin yanki da yawa don kimanta inganci da amincin KX-826 don kula da AGA a cikin mata masu girma (N=160).
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- Youzhi Tong, founder, Chairman, and CEO of Kintor Pharma commented, “We are delighted to see the completion of the enrollment of all subjects in the phase II clinical trial of KX-826, and I would like to give special thanks to all the investigators, subjects and my team who participated in this clinical trial.
- We look forward to receiving preliminary data from this study in Q4 this year, further broadening the clinical potential of KX-826 in female AGA patients, and accelerating KX-826’s phase III clinical trial for male AGA patients in China, so as to meet the treatment needs of people suffering from hair loss as soon as possible.
- The population of those who suffer from hair loss has a large number and tends to be younger, and hair loss is gradually becoming the focus of the whole society.
